Tenofovir Alafenamide is Not a Substrate for Renal Organic Anion Transporters (Oats) and Does Not Exhibit Oat-Dependent Cytotoxicity

Abstract

Background

Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir that shows enhanced antiretroviral effect and reduced plasma tenofovir exposures at approximately one-tenth the clinically approved dose of tenofovir disoproxil fumarate (TDF). Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients. Here, we evaluate the interaction of TAF with OAT1 and OAT3 to assess the potential for its active accumulation in proximal tubules.

Methods

OAT-mediated transport and cytotoxicity (CC₅₀) of TAF and tenofovir were assessed in cells expressing OATs and compared with matched transporter-null cells.

Results

While OAT1 and OAT3 expression increased tenofovir cellular uptake by >70-fold and 8.2-fold, respectively, the expression of either OAT did not significantly change TAF intracellular accumulation under identical conditions. In addition, although tenofovir was significantly more cytotoxic in OAT1- and OAT3-expressing cells (>21 and >3.6 fold change in CC₅₀ values, respectively), TAF in vitro cytotoxicity showed little to no change upon overexpression of either renal transporter (0.5–3.5 fold change in CC₅₀).

Conclusions

Unlike tenofovir, TAF does not interact with renal transporters OAT1 or OAT3 and exhibits no OAT-dependent cytotoxicity. TAF is thus unlikely to actively accumulate in renal proximal tubules in an OAT-dependent manner, supporting the potential for an improved renal safety profile.

References

Kearney

B.P.

, Flaherty

J.F.

, Shah

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595–612.

Motohashi

, Sakurai

, Saito

Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002; 13: 866–874.

Cihlar

, Ho

E.S.

, Lin

D.C.

, Mulato

A.S.

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641–648.

Cihlar

, Bleasby

, Roy

, Pritchard

Antiviral acyclic nucleotide analogs tenofovir and adefovir are substrates for kidney organic anion, but not cation transporters: Implications for renal drug interactions. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October–2 November 2004, Washingtion DC, USA. Abstract A-443.

van Aubel

R.A.

, Smeets

P.H.

, Peters

J.G.

, Bindels

R.J.

, Russel

F.G.

The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13: 595–603.

Cundy

K.C.

, Bidgood

A.M.

, Lynch

, Shaw

J.P.

, Griffin

, Lee

W.A.

Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos 1996; 24: 745–752.

Cundy

K.C.

, Li

Z.H.

, Lee

W.A.

Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos 1996; 24: 315–321.

Sax

P.E.

, Gallant

J.E.

, Klotman

P.E.

Renal safety of tenofovir disoproxil fumarate. AIDS Read 2007; 17: 90–92.

Rodriguez-Nóvoa

, Alvarez

, Labarga

, Soriano

Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9: 545–559.

10.

Ruane

P.J.

, Dejesus

, Berger

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide (TAF) as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013; 63: 449–455.

11.

Sax

, Brar

, Elion

48 week study of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF), each in a single tablet regimen (STR) with elvitegravir, cobicistat, and emtricitabine [E/C/F/TAF versus E/C/F/TDF] for initial HIV treatment. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 10–13 September 2013, Denver, CO, USA. Abstract H-1464d.

12.

Birkus

, Wang

, Liu

Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother 2007; 51: 543–550.

13.

Lee

W.A.

, He

G.X.

, Eisenberg

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005; 49: 1898–1906.

14.

Cihlar

, Ray

A.S.

, Laflamme

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007; 12: 267–272.

15.

Cihlar

, Laflamme

, Fisher

Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother 2009; 53: 150–156.

16.

Uwai

, Ida

, Tsuji

, Katsura

, Inui

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007; 24: 811–815.

17.

E.S.

, Lin

D.C.

, Mendel

D.B.

, Cihlar

Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11: 383–393.

18.

Bam

R.A.

, Birkus

, Babusis

, Cihlar

, Yant

S.R.

Metabolism and antiretroviral activity of tenofovir alafenamide in CD4⁺ T-cells and macrophages from demographically diverse donors. Antivir Ther 2014; doi:10.3851/IMP2767.